BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-30. [PMID: 26274335 DOI: 10.1002/hep.28123] [Cited by in Crossref: 451] [Cited by in F6Publishing: 387] [Article Influence: 64.4] [Reference Citation Analysis]
Number Citing Articles
1 Molinari M, Kaltenmeier C, Samra P, Liu H, Wessel C, Lou Klem M, Dharmayan S, Emmanuel B, Al Harakeh H, Tohme S, Geller D, Tevar A, Hughes CB, Humar A, Bataller R, Behari J. Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients. Annals of Surgery Open 2021;2:e065. [DOI: 10.1097/as9.0000000000000065] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Xu A, Wang B, Fu J, Qin W, Yu T, Yang Z, Lu Q, Chen J, Chen Y, Wang H. Diet-induced hepatic steatosis activates Ras to promote hepatocarcinogenesis via CPT1α. Cancer Lett 2019;442:40-52. [PMID: 30401637 DOI: 10.1016/j.canlet.2018.10.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C. Should Patients With NAFLD/NASH Be Surveyed for HCC? Transplantation 2019;103:39-44. [DOI: 10.1097/tp.0000000000002361] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
4 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yoo ER, Kim D, Vazquez‐montesino LM, Escober JA, Li AA, Tighe SP, Fernandes CT, Cholankeril G, Ahmed A. Diet quality and its association with nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality. Liver Int 2020;40:815-24. [DOI: 10.1111/liv.14374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lee T, Wu J, Yu S, Lin J, Wu M, Wu C. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 2017;141:1307-14. [DOI: 10.1002/ijc.30784] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
7 Rich NE, Singal AG. Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines? Hepatology 2022;75:740-53. [PMID: 34923659 DOI: 10.1002/hep.32284] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Roskilly A, Rowe IA. Surveillance for hepatocellular cancer. Clin Med (Lond). 2018;18:s66-s69. [PMID: 29700096 DOI: 10.7861/clinmedicine.18-2-s66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Billeter AT, Müller PC, Albrecht T, Roessler S, Löffler M, Lemekhova A, Mehrabi A, Müller-Stich BP, Hoffmann K. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis. J Gastrointest Surg 2021;25:1193-202. [PMID: 32378092 DOI: 10.1007/s11605-020-04628-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Thuluvath PJ, Hanish S, Savva Y. Liver Transplantation in Cryptogenic Cirrhosis: Outcome Comparisons Between NASH, Alcoholic, and AIH Cirrhosis. Transplantation 2018;102:656-63. [DOI: 10.1097/tp.0000000000002030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
11 Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00337-6. [PMID: 34294580 DOI: 10.1016/j.dld.2021.06.023] [Reference Citation Analysis]
12 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Reference Citation Analysis]
13 Wu C, Zhou Y, Wang M, Dai G, Liu X, Lai L, Tang S. Bioinformatics Analysis Explores Potential Hub Genes in Nonalcoholic Fatty Liver Disease. Front Genet 2021;12:772487. [PMID: 34777484 DOI: 10.3389/fgene.2021.772487] [Reference Citation Analysis]
14 Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2174-2181. [PMID: 28474143 DOI: 10.1007/s10620-017-4595-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
15 Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00078-x] [Reference Citation Analysis]
16 Liu Y, Li H, Ye N, Luo CJ, Hu YY, Wu H, Gong JP. Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Med Sci Monit 2019;25:6615-23. [PMID: 31479436 DOI: 10.12659/MSM.915722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Takeda M, Sakaguchi T, Hiraide T, Shibasaki Y, Morita Y, Kikuchi H, Ikegami K, Setou M, Konno H, Takeuchi H. Role of caveolin-1 in hepatocellular carcinoma arising from non-alcoholic fatty liver disease. Cancer Sci 2018;109:2401-11. [PMID: 29896915 DOI: 10.1111/cas.13659] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zhang X, Heredia NI, Balakrishnan M, Thrift AP. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018. PLoS One 2021;16:e0252164. [PMID: 34081733 DOI: 10.1371/journal.pone.0252164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wegermann K, Hyun J, Diehl AM. Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer. Clin Liver Dis (Hoboken) 2021;17:6-10. [PMID: 33552478 DOI: 10.1002/cld.1006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Stefan N. Nonalcoholic Fatty Liver Disease and Mortality. Clin Gastroenterol Hepatol 2018;16:1043-5. [PMID: 29474973 DOI: 10.1016/j.cgh.2018.02.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open 2020;10:e036663. [PMID: 32747349 DOI: 10.1136/bmjopen-2019-036663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
22 Kahali B, Halligan B, Speliotes EK. Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:375-91. [PMID: 26676813 DOI: 10.1055/s-0035-1567870] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
23 Ahn SY, Kim SB, Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:4873875. [PMID: 32566546 DOI: 10.1155/2020/4873875] [Reference Citation Analysis]
24 Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, Verhelst X, Van Dorpe J, Van Steenkiste C, Casteleyn C, Lapauw B, Van Vlierberghe H, Geerts A, Devisscher L. Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:1087-104. [PMID: 30259536 DOI: 10.1002/hep.30294] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 16.3] [Reference Citation Analysis]
25 Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med 2019;10:323-34. [PMID: 31572038 DOI: 10.2147/JBM.S186362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
26 Tang Y, Zhang J, Li J, Lei X, Xu D, Wang Y, Li C, Li X, Mao Y. Turnover of bile acids in liver, serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019;1864:1293-304. [DOI: 10.1016/j.bbalip.2019.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
27 Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr 2019;38:2552-7. [PMID: 30573353 DOI: 10.1016/j.clnu.2018.11.030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
28 Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol 2019;18:810-5. [PMID: 31543467 DOI: 10.1016/j.aohep.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
29 Gao J, Xiong R, Xiong D, Zhao W, Zhang S, Yin T, Zhang X, Jiang G, Yin Z. The Adenosine Monophosphate (AMP) Analog, 5-Aminoimidazole-4-Carboxamide Ribonucleotide (AICAR) Inhibits Hepatosteatosis and Liver Tumorigenesis in a High-Fat Diet Murine Model Treated with Diethylnitrosamine (DEN). Med Sci Monit 2018;24:8533-43. [PMID: 30474622 DOI: 10.12659/MSM.910544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Chen J, Chen J, Huang J, Li Z, Gong Y, Zou B, Liu X, Ding L, Li P, Zhu Z, Zhang B, Guo H, Cai C, Li J. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway. Aging (Albany NY) 2019;11:10839-60. [PMID: 31796646 DOI: 10.18632/aging.102488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
31 Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. Int J Mol Sci 2021;22:4173. [PMID: 33920670 DOI: 10.3390/ijms22084173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jun TW, Yeh ML, Yang JD, Chen VL, Nguyen P, Giama NH, Huang CF, Hsing AW, Dai CY, Huang JF, Chuang WL, Roberts LR, Yu ML, Nguyen MH. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int 2018;38:895-902. [PMID: 29045023 DOI: 10.1111/liv.13613] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
33 Sorop A, Constantinescu D, Cojocaru F, Dinischiotu A, Cucu D, Dima SO. Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4997. [PMID: 34066780 DOI: 10.3390/ijms22094997] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Zhang K, Xu Q, Gao Y, Cao H, Lian Y, Li Z, Xu J, Zhong M, Li J, Wei R, Dong J, Jin L. Polysaccharides from Dicliptera chinensis ameliorate liver disturbance by regulating TLR-4/NF-κB and AMPK/Nrf2 signalling pathways. J Cell Mol Med 2020;24:6397-409. [PMID: 32337831 DOI: 10.1111/jcmm.15286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
35 Tompkins SC, Sheldon RD, Rauckhorst AJ, Noterman MF, Solst SR, Buchanan JL, Mapuskar KA, Pewa AD, Gray LR, Oonthonpan L, Sharma A, Scerbo DA, Dupuy AJ, Spitz DR, Taylor EB. Disrupting Mitochondrial Pyruvate Uptake Directs Glutamine into the TCA Cycle away from Glutathione Synthesis and Impairs Hepatocellular Tumorigenesis. Cell Rep 2019;28:2608-2619.e6. [PMID: 31484072 DOI: 10.1016/j.celrep.2019.07.098] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
36 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Reference Citation Analysis]
37 Dechassa ML, Tryndyak V, de Conti A, Xiao W, Beland FA, Pogribny IP. Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma. Molecular Carcinogenesis 2018;57:978-87. [DOI: 10.1002/mc.22818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
38 Best J, Bechmann LP, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2020;18:728-735.e4. [DOI: 10.1016/j.cgh.2019.11.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 18.5] [Reference Citation Analysis]
39 Adams LA, Roberts SK, Strasser SI, Mahady SE, Powell E, Estes C, Razavi H, George J. Nonalcoholic fatty liver disease burden: Australia, 2019-2030. J Gastroenterol Hepatol. 2020;35:1628-1635. [PMID: 32048317 DOI: 10.1111/jgh.15009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
40 Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Eslam M, Wong GL, George J, Romero-Gomez M, Adams LA. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. Clin Gastroenterol Hepatol 2021;19:136-145.e6. [PMID: 32389886 DOI: 10.1016/j.cgh.2020.04.083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
41 Elhence A, Shalimar. Treatment of non-alcoholic fatty liver disease - Current perspectives. Indian J Gastroenterol 2020;39:22-31. [PMID: 32152902 DOI: 10.1007/s12664-020-01021-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
44 Li Y, Sun JP, Wang J, Lu WH, Xie LY, Lv J, Li HX, Yang SF. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice. Biochem Biophys Res Commun 2019;516:858-65. [PMID: 31266632 DOI: 10.1016/j.bbrc.2019.06.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
45 Massoud O, Charlton M. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease 2018;22:201-11. [DOI: 10.1016/j.cld.2017.08.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
46 Elcioglu ZC, Reeves HL. NAFLD-which patients should have hepatocellular carcinoma surveillance? Hepatobiliary Surg Nutr 2017;6:353-5. [PMID: 29152488 DOI: 10.21037/hbsn.2017.06.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Jung YB, Yoo JE, Han DH, Kim KS, Choi JS, Kim DY, Park YN, Choi GH. Clinical and survival outcomes after hepatectomy in patients with non-alcoholic fatty liver and hepatitis B-related hepatocellular carcinoma. HPB (Oxford) 2021;23:1113-22. [PMID: 33309568 DOI: 10.1016/j.hpb.2020.10.027] [Reference Citation Analysis]
48 Zhu C, Tabas I, Schwabe RF, Pajvani UB. Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis. Nat Rev Gastroenterol Hepatol. 2021;18:131-142. [PMID: 33051603 DOI: 10.1038/s41575-020-00365-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
49 Cho JH, Lee JS, Kim HG, Lee HW, Fang Z, Kwon HH, Kim DW, Lee CM, Jeong JW. Ethyl Acetate Fraction of Amomum villosum var. xanthioides Attenuates Hepatic Endoplasmic Reticulum Stress-Induced Non-Alcoholic Steatohepatitis via Improvement of Antioxidant Capacities. Antioxidants (Basel) 2021;10:998. [PMID: 34201527 DOI: 10.3390/antiox10070998] [Reference Citation Analysis]
50 Stefansdottir J, Christensen E, Schiødt FV. Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience. Scandinavian Journal of Gastroenterology 2017;52:768-72. [DOI: 10.1080/00365521.2017.1304985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 Liu X, Xu J. Calling a stage-based treatment model for chronic liver diseases in China mainland. Ann Hepatol 2020;19:585-9. [PMID: 31711913 DOI: 10.1016/j.aohep.2019.09.007] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Chen J, Liu J, Wang Y, Hu X, Zhou F, Hu Y, Yuan Y, Xu Y. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro. Biomed Pharmacother 2017;91:621-31. [PMID: 28486193 DOI: 10.1016/j.biopha.2017.04.125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
53 Tran NH. Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. Curr Oncol Rep. [DOI: 10.1007/s11912-021-01160-5] [Reference Citation Analysis]
54 Zheng Y, Zhang X, Lu J, Liu S, Qian Y. Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Med 2021;10:7347-59. [PMID: 34414679 DOI: 10.1002/cam4.4223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019;9:19785. [PMID: 31874999 DOI: 10.1038/s41598-019-56235-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
56 Acharya SK, Bopanna S. Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different? J Clin Exp Hepatol 2020;10:518-24. [PMID: 33029058 DOI: 10.1016/j.jceh.2020.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Loosen SH, Demir M, Kunstein A, Jördens M, Qvarskhava N, Luedde M, Luedde T, Roderburg C, Kostev K. Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2021;9:e002243. [PMID: 34049870 DOI: 10.1136/bmjdrc-2021-002243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016;59:1112-1120. [PMID: 27101131 DOI: 10.1007/s00125-016-3952-1] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 13.8] [Reference Citation Analysis]
59 Li D, Liu F, Wang X, Li X. Apple Polyphenol Extract Alleviates High-Fat-Diet-Induced Hepatic Steatosis in Male C57BL/6 Mice by Targeting LKB1/AMPK Pathway. J Agric Food Chem 2019;67:12208-18. [DOI: 10.1021/acs.jafc.9b05495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
60 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
61 Birerdinc A, Younossi ZM. Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Ann Hepatol 2018;17:11-3. [PMID: 29311407 DOI: 10.5604/01.3001.0010.7530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
62 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
63 Lee HS, Lee SJ, Ho JN, Cho HY. Preventive Effect of Fermented Chestnut Inner Shell Extract on Obesity-Induced Hepatic Steatosis. Prev Nutr Food Sci 2020;25:32-40. [PMID: 32292753 DOI: 10.3746/pnf.2020.25.1.32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
64 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123-33. [PMID: 28802062 DOI: 10.1002/hep.29466] [Cited by in Crossref: 804] [Cited by in F6Publishing: 699] [Article Influence: 201.0] [Reference Citation Analysis]
65 Nyberg LM, Cheetham TC, Patton HM, Yang SJ, Chiang KM, Caparosa SL, Stern JA, Nyberg AH. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. Hepatol Commun 2021;5:83-96. [PMID: 33437903 DOI: 10.1002/hep4.1625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8263-8276 [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 252] [Cited by in F6Publishing: 225] [Article Influence: 50.4] [Reference Citation Analysis]
67 Klein S, Dufour JF. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepat Oncol 2017;4:83-98. [PMID: 30191057 DOI: 10.2217/hep-2017-0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
68 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 288] [Article Influence: 43.1] [Reference Citation Analysis]
69 Sougiannis AT, VanderVeen BN, Cranford TL, Enos RT, Velazquez KT, McDonald S, Bader JE, Chatzistamou I, Fan D, Murphy EA. Impact of weight loss and partial weight regain on immune cell and inflammatory markers in adipose tissue in male mice. J Appl Physiol (1985) 2020;129:909-19. [PMID: 32853106 DOI: 10.1152/japplphysiol.00356.2020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M, Castellanos-fernandez M, George J, Jacobson IM, Bugianesi E, Wong VW, Arrese M, de Ledinghen V, Romero-gomez M, Mendez-sanchez N, Ahmed A, Wong R, Papatheodoridis G, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2019;17:1625-1633.e1. [DOI: 10.1016/j.cgh.2018.11.033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 14.7] [Reference Citation Analysis]
71 Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106-117. [PMID: 28174094 DOI: 10.1016/j.pharmthera.2017.02.010] [Cited by in Crossref: 120] [Cited by in F6Publishing: 124] [Article Influence: 24.0] [Reference Citation Analysis]
72 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
73 Soofi A, Wolf KI, Ranghini EJ, Amin MA, Dressler GR. The kielin/chordin-like protein KCP attenuates nonalcoholic fatty liver disease in mice. Am J Physiol Gastrointest Liver Physiol 2016;311:G587-98. [PMID: 27514479 DOI: 10.1152/ajpgi.00165.2016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
74 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
75 Longo M, Meroni M, Paolini E, Macchi C, Dongiovanni P. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? Metabolism 2021;117:154708. [PMID: 33444607 DOI: 10.1016/j.metabol.2021.154708] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
76 Cai JL, Zhu GQ, Du JX, Wang B, Wan JL, Xiao K, Dai Z. Identification and validation of a new gene signature predicting prognosis of hepatocellular carcinoma patients by network analysis of stemness indices. Expert Rev Gastroenterol Hepatol 2021;15:699-709. [PMID: 33131341 DOI: 10.1080/17474124.2021.1845142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Zhang C, Wang P, Li Y, Huang C, Ni W, Chen Y, Shi J, Chen G, Hu X, Ye M, Duan S, Wang K. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Anat Rec (Hoboken) 2019;302:193-200. [PMID: 30312023 DOI: 10.1002/ar.23954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
78 Koh YX, Tan HJ, Liew YX, Syn N, Teo JY, Lee SY, Goh BKP, Goh GBB, Chan CY. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma. J Am Coll Surg 2019;229:467-478.e1. [PMID: 31398386 DOI: 10.1016/j.jamcollsurg.2019.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
79 Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, Magini G, Frossard JL, Bascaron ME, Vernaz N, Zampaglione L, Negro F, Goossens N. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep 2021;3:100231. [PMID: 33748726 DOI: 10.1016/j.jhepr.2021.100231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
80 Milroy CM. Fatty Liver and the Forensic Pathologist. Acad Forensic Pathol 2018;8:296-310. [PMID: 31240043 DOI: 10.1177/1925362118782061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Banini BA, Sanyal AJ. NAFLD-related HCC. Adv Cancer Res 2021;149:143-69. [PMID: 33579423 DOI: 10.1016/bs.acr.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
82 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Reference Citation Analysis]
83 Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:1061-9. [PMID: 28960360 DOI: 10.1111/apt.14342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
84 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Reference Citation Analysis]
85 Ning L, Liu R, Lou X, Du H, Chen W, Zhang F, Li S, Chen X, Xu G. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. European Journal of Gastroenterology & Hepatology 2019;31:735-42. [DOI: 10.1097/meg.0000000000001398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 4.7] [Reference Citation Analysis]
86 Huang B, Yao Y, Li Y, Yang H, Liu H, Liu H, Li D, Shu W, Chen M. Proteomics approach to investigate dynamic protein profile involved in high fat diet-induced fatty liver disease in rats. J Toxicol Pathol 2019;32:223-32. [PMID: 31719749 DOI: 10.1293/tox.2018-0045] [Reference Citation Analysis]
87 Wilman HR, Kelly M, Garratt S, Matthews PM, Milanesi M, Herlihy A, Gyngell M, Neubauer S, Bell JD, Banerjee R, Thomas EL. Characterisation of liver fat in the UK Biobank cohort. PLoS One. 2017;12:e0172921. [PMID: 28241076 DOI: 10.1371/journal.pone.0172921] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 8.4] [Reference Citation Analysis]
88 Cheng F, Ma C, Wang X, Zhai C, Wang G, Xu X, Mu J, Li C, Wang Z, Zhang X, Yue W, Du X, Lian Y, Zhu W, Yin X, Wei Z, Song W, Wang Q. Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study. BMC Complement Altern Med 2017;17:203. [PMID: 28388904 DOI: 10.1186/s12906-017-1707-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
89 Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules 2017;22:E191. [PMID: 28125040 DOI: 10.3390/molecules22020191] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 26.4] [Reference Citation Analysis]
90 Tran C, Kim JJ, Feld JJ, Wong WW. Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation. CanLivJ 2021;4:360-9. [DOI: 10.3138/canlivj-2021-0011] [Reference Citation Analysis]
91 Xu J, Wang R, You S, Zhang L, Zheng P, Ji G, Liu B. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial. Trials 2020;21:512. [PMID: 32522273 DOI: 10.1186/s13063-020-04362-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Sarkar S, Lipworth L, Kabagambe EK, Bian A, Stewart TG, Blot WJ, Ikizler TA, Hung AM. A Description of Risk Factors for Non-alcoholic Fatty Liver Disease in the Southern Community Cohort Study: A Nested Case-Control Study. Front Nutr 2020;7:71. [PMID: 32671089 DOI: 10.3389/fnut.2020.00071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
93 Cardoso AC, Cravo C, Calçado FL, Rezende G, Campos CFF, Neto JMA, Luz RP, Soares JAS, Moraes-coelho HS, Leite NC, Perez RM, Villela-nogueira CA. The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort. European Journal of Gastroenterology & Hepatology 2020;32:231-8. [DOI: 10.1097/meg.0000000000001496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
94 Armandi A, Bugianesi E. Natural history of NASH. Liver Int 2021;41 Suppl 1:78-82. [PMID: 34155792 DOI: 10.1111/liv.14910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Cunha GM, Correa de Mello LL, Hasenstab KA, Spina L, Bussade I, Prata Mesiano JM, Coutinho W, Guzman G, Sajoux I. MRI estimated changes in visceral adipose tissue and liver fat fraction in patients with obesity during a very low-calorie-ketogenic diet compared to a standard low-calorie diet. Clin Radiol 2020;75:526-32. [PMID: 32204895 DOI: 10.1016/j.crad.2020.02.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
96 Golabi P, Otgonsuren M, Cable R, Felix S, Koenig A, Sayiner M, Younossi ZM. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes. 2016;14:18. [PMID: 26860700 DOI: 10.1186/s12955-016-0420-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
97 Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2016;17:1937-46. [DOI: 10.1080/14656566.2016.1225727] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
98 Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, Marotta P, Elkhashab M, Bajaj HS, Estes C, Razavi H. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ Open 2020;8:E429-36. [PMID: 32518095 DOI: 10.9778/cmajo.20190212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
99 Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Nishimura D, Toyoda H, Kumada T, Goto H, Hirooka Y. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients: Noninvasive fibrosis markers for non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2019;34:207-14. [DOI: 10.1111/jgh.14448] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
100 Lee GH, Phyo WW, Loo WM, Kwok R, Ahmed T, Shabbir A, So J, Koh CJ, Hartono JL, Muthiah M, Lim K, Tan PS, Lee YM, Lim SG, Dan YY. Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. World J Hepatol 2020; 12(12): 1228-1238 [PMID: 33442450 DOI: 10.4254/wjh.v12.i12.1228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
102 Sekhon AK, Gollapalli A, Kaur D, Janssen B, Stevens ML, Valerio F, Sierra-Hoffman MA. A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH). Am J Case Rep 2021;22:e932961. [PMID: 34826302 DOI: 10.12659/AJCR.932961] [Reference Citation Analysis]
103 Shah RA, Alkhouri N, Kowdley KV. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. Expert Opinion on Emerging Drugs 2020;25:251-60. [DOI: 10.1080/14728214.2020.1796968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
104 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
105 Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019;39 Suppl 1:19-31. [PMID: 30851228 DOI: 10.1111/liv.14095] [Cited by in Crossref: 104] [Cited by in F6Publishing: 105] [Article Influence: 34.7] [Reference Citation Analysis]
106 Lu L, Chen C, Li Y, Guo W, Zhang S, Brockman J, Shikany JM, Kahe K. Magnesium intake is inversely associated with risk of non-alcoholic fatty liver disease among American adults. Eur J Nutr 2021. [PMID: 34741649 DOI: 10.1007/s00394-021-02732-8] [Reference Citation Analysis]
107 Alves VA, D'Albuquerque LA. Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey. Clinics (Sao Paulo) 2016;71:423-4. [PMID: 27626470 DOI: 10.6061/clinics/2016(08)02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
108 Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Toyoda H, Kumada T, Fujishiro M. Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease. Nutr Cancer 2020;72:884-91. [PMID: 31433263 DOI: 10.1080/01635581.2019.1653474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Pritulina YG, Prokopenko SE, Kordenko AA, Atiakshin DA, Lobanov VL. [Evaluation of the effect of remaxol on hepatocytes in non-alcoholic fatty liver dystrophy modeling in laboratory C57BL/6 mice]. Arkh Patol 2019;81:64-9. [PMID: 31626206 DOI: 10.17116/patol20198105164] [Reference Citation Analysis]
110 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
111 Fasolato S, Pigozzo S, Pontisso P, Angeli P, Ruscica M, Savarino E, De Martin S, Lupo MG, Ferri N. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. J Clin Med 2020;9:E3134. [PMID: 32998342 DOI: 10.3390/jcm9103134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
112 Personeni N, Rimassa L. Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment Strategies. J Oncol Pract 2017;13:368-9. [PMID: 28605613 DOI: 10.1200/JOP.2017.024604] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
113 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Reference Citation Analysis]
114 Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
115 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
116 Wei Z, Ren Z, Hu S, Gao Y, Sun R, Lv S, Yang G, Yu Z, Kan Q. Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease. Cancer Med 2020;9:1254-62. [PMID: 31860170 DOI: 10.1002/cam4.2777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Chen M, Wong CM. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer 2020;19:44. [PMID: 32111216 DOI: 10.1186/s12943-020-01172-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 24.0] [Reference Citation Analysis]
119 Yao S, Wei Y, Ye Z, Chen J, Duan T, Zhang Z, Song B. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging. J Magn Reson Imaging 2021. [PMID: 34121266 DOI: 10.1002/jmri.27783] [Reference Citation Analysis]
120 Ma C, Liu Y, He S, Zeng J, Li P, Ma C, Ping F, Zhang H, Xu L, Li W, Li Y. Association Between Leukocyte Mitochondrial DNA Copy Number and Non-alcoholic Fatty Liver Disease in a Chinese Population Is Mediated by 8-Oxo-2'-Deoxyguanosine. Front Med (Lausanne) 2020;7:536. [PMID: 33015093 DOI: 10.3389/fmed.2020.00536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Afzali N, Ebadi SS, Afzali H, Sharif MR, Vazirian M, Ebadi SA, Shahkarami V, Rahimi H. Effect of Beta vulgaris Extract on Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.102125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
122 Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15:137-151. [PMID: 29317776 DOI: 10.1038/nrgastro.2017.169] [Cited by in Crossref: 157] [Cited by in F6Publishing: 174] [Article Influence: 39.3] [Reference Citation Analysis]
123 Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E3863. [PMID: 32485838 DOI: 10.3390/ijms21113863] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
124 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
125 Thompson SM, Wang J, Chandan VS, Glaser KJ, Roberts LR, Ehman RL, Venkatesh SK. MR elastography of hepatocellular carcinoma: Correlation of tumor stiffness with histopathology features-Preliminary findings. Magn Reson Imaging 2017;37:41-5. [PMID: 27845245 DOI: 10.1016/j.mri.2016.11.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
126 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Zhu LY, Liu C, Li ZR, Niu C, Wu J. NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water. Lab Invest 2021;101:588-99. [PMID: 33526807 DOI: 10.1038/s41374-021-00535-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Kim NG, Nguyen PP, Dang H, Kumari R, Garcia G, Esquivel CO, Nguyen MH. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015: Long-Term Survival in Patients With HCC. Cancer 2018;124:2588-98. [DOI: 10.1002/cncr.31373] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
129 Sunny NE, Bril F, Cusi K. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. Trends Endocrinol Metab. 2017;28:250-260. [PMID: 27986466 DOI: 10.1016/j.tem.2016.11.006] [Cited by in Crossref: 118] [Cited by in F6Publishing: 119] [Article Influence: 19.7] [Reference Citation Analysis]
130 Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metabolism 2016;65:1007-16. [DOI: 10.1016/j.metabol.2015.12.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
131 Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? WJH 2022; 14(2):354-71. [DOI: 10.4254/wjh.v14.i2.354] [Reference Citation Analysis]
132 Xie Z, Li H, Tan W, Yang L, Ma X, Li W, Wang Q, Shang C, Chen Y. Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States. Front Nutr 2022;8:795391. [DOI: 10.3389/fnut.2021.795391] [Reference Citation Analysis]
133 Wang X, Dong LY, Gai QJ, Ai WL, Wu Y, Xiao WC, Zhang J, An W. Lack of Augmenter of Liver Regeneration Disrupts Cholesterol Homeostasis of Liver in Mice by Inhibiting the AMPK Pathway. Hepatol Commun 2020;4:1149-67. [PMID: 32766475 DOI: 10.1002/hep4.1532] [Reference Citation Analysis]
134 Nishimura N, Kaji K, Kitade M, Aihara Y, Sato S, Seki K, Sawada Y, Takaya H, Okura Y, Kawaratani H, Moriya K, Namisaki T, Mitoro A, Yoshiji H. Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats. BMC Cancer 2018;18:1164. [PMID: 30477453 DOI: 10.1186/s12885-018-5099-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
135 Ki Kim S, Ueda Y, Hatano E, Kakiuchi N, Takeda H, Goto T, Shimizu T, Yoshida K, Ikura Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Uemoto S, Chiba T, Ogawa S, Marusawa H. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma: Characteristics of genetic aberrations of hepatocellular carcinoma developed in nonalcoholic fatty liver disease. Int J Cancer 2016;139:2512-8. [DOI: 10.1002/ijc.30379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
136 Funuyet-salas J, Martín-rodríguez A, Conrad R, Pérez-san-gregorio MÁ. Psychological Biomarker Profile in NAFLD/NASH with Advanced Fibrosis. In: Romero-gomez M, editor. NAFLD and NASH. Cham: Springer International Publishing; 2020. pp. 205-23. [DOI: 10.1007/978-3-030-37173-9_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
137 Meroni M, Longo M, Lombardi R, Paolini E, Macchi C, Corsini A, Sirtori CR, Fracanzani AL, Ruscica M, Dongiovanni P. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021. [PMID: 34677008 DOI: 10.1002/hep4.1830] [Reference Citation Analysis]
138 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
139 Vopham T, Kim NJ, Berry K, Mendoza JA, Kaufman JD, Ioannou GN. PM2.5 air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample. Environmental Research 2022. [DOI: 10.1016/j.envres.2022.113611] [Reference Citation Analysis]
140 Zhang D, Xu A. Application of dual-source CT perfusion imaging and MRI for the diagnosis of primary liver cancer. Oncol Lett 2017;14:5753-8. [PMID: 29113204 DOI: 10.3892/ol.2017.6170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
141 Liu L, Xie S, Teng Y, Deng Z, Chen K, Liu H, Huo R, Liang X, Guo P, Yang D, Ma L, Xiang B, Li L, Zhong J. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol 2022;11:783339. [DOI: 10.3389/fonc.2021.783339] [Reference Citation Analysis]
142 Kim G, Lee HC, Choe J, Kim M, Lee MJ, Chang H, Bae IY, Kim H, An J, Shim JH, Kim KM, Lim Y. Association between non-alcoholic fatty liver disease and cancer incidence rate. Journal of Hepatology 2018;68:140-6. [DOI: 10.1016/j.jhep.2017.09.012] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 15.3] [Reference Citation Analysis]
143 Yang M, Khoukaz L, Qi X, Kimchi ET, Staveley-O'Carroll KF, Li G. Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. Biomedicines 2021;9:1893. [PMID: 34944709 DOI: 10.3390/biomedicines9121893] [Reference Citation Analysis]
144 Linares I, Hamar M, Selzner N, Selzner M. Steatosis in Liver Transplantation: Current Limitations and Future Strategies. Transplantation 2019;103:78-90. [DOI: 10.1097/tp.0000000000002466] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 10.3] [Reference Citation Analysis]
145 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 171] [Article Influence: 31.0] [Reference Citation Analysis]
146 Wang L, Zhu M, Cao L, Yao M, Lu Y, Wen X, Zhang Y, Ning J, Long H, Zhu Y, Hu G, Dang S, Fu Q, Chen L, Zhang X, Zhao J, Gao Z, Nan Y, Lu F. Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study. J Clin Transl Hepatol 2019;7:313-21. [PMID: 31915600 DOI: 10.14218/JCTH.2019.00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
147 Luo X, Li H, Ma L, Zhou J, Guo X, Woo SL, Pei Y, Knight LR, Deveau M, Chen Y, Qian X, Xiao X, Li Q, Chen X, Huo Y, McDaniel K, Francis H, Glaser S, Meng F, Alpini G, Wu C. Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice. Gastroenterology 2018;155:1971-1984.e4. [PMID: 30213555 DOI: 10.1053/j.gastro.2018.09.010] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 19.0] [Reference Citation Analysis]
148 Goh GB, McCullough AJ. Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016;61:1226-33. [PMID: 27003142 DOI: 10.1007/s10620-016-4095-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
149 Peng Y, Wei Q, He Y, Xie Q, Liang Y, Zhang L, Xia Y, Li Y, Chen W, Zhao J, Chai J. ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. Expert Rev Gastroenterol Hepatol 2020;14:383-400. [PMID: 32240595 DOI: 10.1080/17474124.2020.1748010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
150 Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. JGH Open 2018;2:235-41. [PMID: 30483595 DOI: 10.1002/jgh3.12070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
151 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
152 Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
153 Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703. [PMID: 30136293 DOI: 10.1111/apt.14937] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 17.8] [Reference Citation Analysis]
154 Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG 3rd, Tate JP, Re VL 3rd, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. J Gen Intern Med 2020;35:2025-34. [PMID: 32342483 DOI: 10.1007/s11606-020-05782-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). CanLivJ 2022;5:61-90. [DOI: 10.3138/canlivj-2021-0030] [Reference Citation Analysis]
156 Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1525. [PMID: 32102237 DOI: 10.3390/ijms21041525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
157 Tan XP, Zhou K, Zeng QL, Yuan YF, Chen W. Influence of AFP on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma. Clin Exp Med 2022. [PMID: 35293607 DOI: 10.1007/s10238-022-00813-4] [Reference Citation Analysis]
158 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Reference Citation Analysis]
159 Wang J, Yin G, Bian H, Yang J, Zhou P, Yan K, Liu C, Chen P, Zhu J, Li Z, Xue T. LncRNA XIST upregulates TRIM25 via negatively regulating miR-192 in hepatitis B virus-related hepatocellular carcinoma. Mol Med 2021;27:41. [PMID: 33858324 DOI: 10.1186/s10020-021-00278-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
160 Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01183-6. [PMID: 34768009 DOI: 10.1016/j.cgh.2021.11.004] [Reference Citation Analysis]
161 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
162 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
163 Zhu GQ, Wang K, Wang B, Zhou YJ, Yang Y, Chen EB, Zhou ZJ, Zhou SL, Shi YH, Zhou J, Dai Z. Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization. Cancer Manag Res 2019;11:63-79. [PMID: 30588111 DOI: 10.2147/CMAR.S186150] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
164 Chang T, Hsu N, Chen S, Hsu I, Lee M, Lu S. Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study. Viruses 2022;14:984. [DOI: 10.3390/v14050984] [Reference Citation Analysis]
165 Wong CR, Lim JK. Increasing contribution of non-alcoholic fatty liver disease to hepatocellular carcinoma incidence and mortality in U.S. Medicare. Hepatobiliary Surg Nutr 2019;8:506-8. [PMID: 31673540 DOI: 10.21037/hbsn.2019.04.06] [Reference Citation Analysis]
166 Sayiner M, Younossi ZM. Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas. Hepat Oncol 2016;3:101-3. [PMID: 30191030 DOI: 10.2217/hep-2016-0002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
167 Chow JC, Wong GL, Chan AW, Shu SS, Chan CK, Leung JK, Choi PC, Chim AM, Chan HL, Wong VW. Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness: Repeating liver stiffness measurements. Journal of Gastroenterology and Hepatology 2019;34:241-8. [DOI: 10.1111/jgh.14311] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
168 Huang DQ, Singal AG, Kono Y, Tan DJ, El-serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism 2022. [DOI: 10.1016/j.cmet.2022.05.003] [Reference Citation Analysis]
169 Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, Tanwar S, Pizzo E, O'Beirne J, Tsochatzis E, Parkes J, Rosenberg W. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19:122. [PMID: 31296161 DOI: 10.1186/s12876-019-1039-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
170 Liao S, Chen H, Liu M, Gan L, Li C, Zhang W, Lv L, Mei Z. Aquaporin 9 inhibits growth and metastasis of hepatocellular carcinoma cells via Wnt/β-catenin pathway. Aging (Albany NY) 2020;12:1527-44. [PMID: 31969493 DOI: 10.18632/aging.102698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
171 Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A;  Global Nonalcoholic Steatohepatitis Council. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2019;17:748-755.e3. [PMID: 29908364 DOI: 10.1016/j.cgh.2018.05.057] [Cited by in Crossref: 219] [Cited by in F6Publishing: 217] [Article Influence: 54.8] [Reference Citation Analysis]
172 Chin KM, Prieto M, Cheong CK, Di Martino M, Ielpo B, Goh BKP, Koh YX. Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature. HPB (Oxford) 2021;23:1164-74. [PMID: 33608215 DOI: 10.1016/j.hpb.2021.01.009] [Reference Citation Analysis]
173 Walker S. New Medications in the Treatment of Nonalcoholic Steatohepatitis. Hosp Pharm 2018;53:146-7. [PMID: 30147133 DOI: 10.1177/0018578718763098] [Reference Citation Analysis]
174 White DL, Kanwal F, Jiao L, El-serag HB. Epidemiology of Hepatocellular Carcinoma. In: Carr BI, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2016. pp. 3-24. [DOI: 10.1007/978-3-319-34214-6_1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
175 Tovoli F, Ferri S, Piscaglia F. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. Curr Pharm Des 2020;26:3909-14. [PMID: 32348210 DOI: 10.2174/1381612826666200429093648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
176 Haam J, Lee YK, Suh E, Kim Y. Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults. Diagnostics 2022;12:1199. [DOI: 10.3390/diagnostics12051199] [Reference Citation Analysis]
177 Zhang Y, Boktour MR. Effects of Share 35 Policy on Liver Transplantation Outcomes for Patients With Nonalcoholic Steatohepatitis. Prog Transplant 2019;29:248-53. [PMID: 31146627 DOI: 10.1177/1526924819854481] [Reference Citation Analysis]
178 Dreval K, Tryndyak V, de Conti A, Beland FA, Pogribny IP. Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis. Front Genet 2019;10:486. [PMID: 31191608 DOI: 10.3389/fgene.2019.00486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
179 Van Treeck BJ, Mounajjed T, Moreira RK, Orujov M, Allende DS, Bellizzi AM, Lagana SM, Davila JI, Jessen E, Graham RP. Transcriptomic and Proteomic Analysis of Steatohepatitic Hepatocellular Carcinoma Reveals Novel Distinct Biologic Features. Am J Clin Pathol 2021;155:87-96. [PMID: 32885245 DOI: 10.1093/ajcp/aqaa114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
180 Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. [PMID: 34118091 DOI: 10.1111/joim.13343] [Reference Citation Analysis]
181 Sha M, Jeong S, Xia Q. Does Donor Allograft Microsteatosis Matter? Comparison of Outcomes in Liver Transplantation With a Propensity-Matched Cohort. Liver Transpl 2019;25:1723-4. [PMID: 31424625 DOI: 10.1002/lt.25624] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
182 Zhou Z, Deng L, Hu L, Ren Q, Cai Z, Wang B, Li Z, Zhang L. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis. Eur J Pharmacol 2020;882:173300. [PMID: 32592770 DOI: 10.1016/j.ejphar.2020.173300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
183 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Reference Citation Analysis]
184 Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Transl Gastroenterol Hepatol 2019;4:72. [PMID: 31728429 DOI: 10.21037/tgh.2019.09.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
185 Cannella R, Borhani AA, Tublin M, Behari J, Furlan A. Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Abdom Radiol (NY) 2019;44:1816-24. [PMID: 30788556 DOI: 10.1007/s00261-019-01931-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
186 Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T. Nonalcoholic Fatty Liver Disease. Handb Exp Pharmacol 2020. [PMID: 32185502 DOI: 10.1007/164_2020_352] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opin Drug Discov 2021;16:125-34. [PMID: 33086894 DOI: 10.1080/17460441.2020.1811674] [Reference Citation Analysis]
188 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
189 Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13:688-694. [PMID: 31701393 DOI: 10.1007/s12072-019-09995-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
190 Huang DH, Jian J, Li S, Zhang Y, Liu LZ. TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway. Int J Mol Med 2019;44:2113-22. [PMID: 31638175 DOI: 10.3892/ijmm.2019.4371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
191 Pennisi G, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Boursier J, Berzigotti A, Eslam M, Ampuero J, Benmassaoud A, La Mantia C, Mendoza YP, George J, Craxì A, Camma' C, de Ledinghen V, Petta S. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. Aliment Pharmacol Ther 2022. [PMID: 34988994 DOI: 10.1111/apt.16763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
192 Aspichueta P. Lipid-rich environment: a key role promoting carcinogenesis in obesity-related non-alcoholic fatty liver disease. Gut 2018;67:1376-7. [PMID: 29540438 DOI: 10.1136/gutjnl-2018-316047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
193 Ji Y, Elkin K, Yip J, Guan L, Han W, Ding Y. From circadian clocks to non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2019;13:1107-12. [DOI: 10.1080/17474124.2019.1684899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
194 Chen YJ, Chueh LY, Lee SY, Ma PF, Chen PC, Hsu SH. Coordinated regulation of miR-27 by insulin/CREB/Hippo contributes to insulin resistance. Cell Signal 2021;81:109930. [PMID: 33515696 DOI: 10.1016/j.cellsig.2021.109930] [Reference Citation Analysis]
195 Hughey CC, Trefts E, Bracy DP, James FD, Donahue EP, Wasserman DH. Glycine N-methyltransferase deletion in mice diverts carbon flux from gluconeogenesis to pathways that utilize excess methionine cycle intermediates. J Biol Chem 2018;293:11944-54. [PMID: 29891549 DOI: 10.1074/jbc.RA118.002568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
196 Kim MN, Lo CH, Corey KE, Liu PH, Ma W, Zhang X, Jovani M, Song M, Chan AT, Simon TG. Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women. Metabolism 2020;113:154398. [PMID: 33058854 DOI: 10.1016/j.metabol.2020.154398] [Reference Citation Analysis]
197 Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlouf H, Goodman Z. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun 2017;1:421-8. [PMID: 29404470 DOI: 10.1002/hep4.1054] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
198 Kim HY. Biopsy-proven Non-alcoholic Fatty Liver Disease and Incident Cancer. Korean J Gastroenterol 2021;78:362-3. [DOI: 10.4166/kjg.2021.158] [Reference Citation Analysis]
199 Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, Cinar R, Ståhlman M, Sikanic N, Park JK, Deshmukh S, Harzandi AM, Kuijpers T, Grøtli M, Elsässer SJ, Piening BD, Snyder M, Smith U, Nielsen J, Bäckhed F, Kunos G, Uhlen M, Boren J, Mardinoglu A. Network analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol 2017;13:938. [PMID: 28827398 DOI: 10.15252/msb.20177703] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 11.8] [Reference Citation Analysis]
200 Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. Hepatol Commun 2019;3:1459-71. [PMID: 31701070 DOI: 10.1002/hep4.1419] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
201 Lavekar AS, Deshpande A, Raje D. Comparison of knowledge and awareness between consultant physicians and resident doctors about non-alcoholic fatty liver disease. Clin Exp Hepatol 2020;6:374-83. [PMID: 33511287 DOI: 10.5114/ceh.2020.102152] [Reference Citation Analysis]
202 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Reference Citation Analysis]
203 Traussnigg S, Halilbasic E, Hofer H, Munda P, Stojakovic T, Fauler G, Kashofer K, Krssak M, Wolzt M, Trauner M. Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. Wien Klin Wochenschr 2021;133:441-51. [PMID: 32930860 DOI: 10.1007/s00508-020-01735-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Kim D, Cholankeril G, Li AA, Kim W, Tighe SP, Hameed B, Kwo PY, Harrison SA, Younossi ZM, Ahmed A. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Liver Int 2019;39:1661-71. [PMID: 31081997 DOI: 10.1111/liv.14135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
205 Zhu L, Jiang J, Zhai X, Baecker A, Peng H, Qian J, Zhou M, Song C, Zhou Y, Xu J, Liu H, Hang D, Hu Z, Shen H, Zhang ZF, Zhu F. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study. Liver Int. 2019;39:70-80. [PMID: 30025200 DOI: 10.1111/liv.13933] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
206 Simon TG, Chan AT. Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin-In Reply. JAMA Oncol 2019;5:911-2. [PMID: 31046066 DOI: 10.1001/jamaoncol.2019.0630] [Reference Citation Analysis]
207 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
208 Umetsu S, Mizukami H, Saito T, Uchida C, Igawa A, Kudo K, Itabashi C, Osonoi S, Danyang G, Sasaki T, Yagihashi S, Hakamada K. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Sci Rep 2020;10:1156. [PMID: 31980687 DOI: 10.1038/s41598-020-57883-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Xiong G, Huang C, Zou Y, Tao Z, Zou J, Huang J, M.a B. Associations of Urinary Phytoestrogen Concentrations with Nonalcoholic Fatty Liver Disease among Adults. Journal of Healthcare Engineering 2022;2022:1-13. [DOI: 10.1155/2022/4912961] [Reference Citation Analysis]
210 Chen Y, Yang X, Chen Y, Chen G, Winkler CA, An P, Lyu J. Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma. BMC Cancer 2021;21:615. [PMID: 34039309 DOI: 10.1186/s12885-021-08245-1] [Reference Citation Analysis]
211 Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia: Burden of fatty liver in Australia. Journal of Gastroenterology and Hepatology 2018;33:1-11. [DOI: 10.1111/jgh.14270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
212 Vinaixa C, Selzner N, Berenguer M. Fat and liver transplantation: clinical implications. Transpl Int 2018;31:828-37. [DOI: 10.1111/tri.13288] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
213 Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, Hu TH, Huang JF, Jang BK, Jun DW, Kao JH, Lee JW, Lin HC, Razavi-Shearer K, Seto WK, Wong GL, Wong VW, Razavi H. Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther 2020;51:801-11. [PMID: 32133676 DOI: 10.1111/apt.15673] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
214 Huang P, Yang L, Liu Y, Jiang Y, Li Y, Chen Z, Song H, Zheng P. Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway. Evid Based Complement Alternat Med 2022;2022:1124901. [PMID: 35035496 DOI: 10.1155/2022/1124901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Yu H, Yang F, Zhong W, Jiang X, Zhang F, Ji X, Xue M, Qiu Y, Yu J, Hu X, Chen J, Bao Z. Secretory Galectin-3 promotes hepatic steatosis via regulation of the PPARγ/CD36 signaling pathway. Cell Signal 2021;84:110043. [PMID: 33991615 DOI: 10.1016/j.cellsig.2021.110043] [Reference Citation Analysis]
216 Yan JH, Guan BJ, Gao HY, Peng XE. Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018;97:e12271. [PMID: 30212963 DOI: 10.1097/MD.0000000000012271] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 11.3] [Reference Citation Analysis]
217 Corrao S, Natoli G, Argano C. Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis. Eur J Gastroenterol Hepatol 2021;33:62-8. [PMID: 32091438 DOI: 10.1097/MEG.0000000000001684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
218 Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? Journal of Hepatology 2018;68:326-34. [DOI: 10.1016/j.jhep.2017.10.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 19.0] [Reference Citation Analysis]
219 Zeng F, Shi M, Xiao H, Chi X. WGCNA-Based Identification of Hub Genes and Key Pathways Involved in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2021;2021:5633211. [PMID: 34938809 DOI: 10.1155/2021/5633211] [Reference Citation Analysis]
220 Lee YG, Jeon TI. Modulation of the Autophagy-lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules. Molecules 2020;25:E1580. [PMID: 32235537 DOI: 10.3390/molecules25071580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
221 Loong TC, Wei JL, Leung JC, Wong GL, Shu SS, Chim AM, Chan AW, Choi PC, Tse YK, Chan HL, Wong VW. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2017;32:1363-1369. [PMID: 27936280 DOI: 10.1111/jgh.13671] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
222 Zhu GQ, Yang Y, Chen EB, Wang B, Xiao K, Shi SM, Zhou ZJ, Zhou SL, Wang Z, Shi YH, Fan J, Zhou J, Liu TS, Dai Z. Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. J Transl Med 2019;17:203. [PMID: 31215439 DOI: 10.1186/s12967-019-1946-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
223 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
224 Bengtsson B, Stål P, Wahlin S, Björkström NK, Hagström H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int 2019;39:1098-108. [PMID: 30829446 DOI: 10.1111/liv.14087] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
225 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
226 Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018;11:92-94. [PMID: 30992797 DOI: 10.1002/cld.710] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
227 Tada T, Nishimura T, Yoshida M, Iijima H. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. J Med Ultrasonics 2020;47:511-20. [DOI: 10.1007/s10396-020-01058-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
228 Fan J, Kim S, Wong VW. New trends on obesity and NAFLD in Asia. Journal of Hepatology 2017;67:862-73. [DOI: 10.1016/j.jhep.2017.06.003] [Cited by in Crossref: 348] [Cited by in F6Publishing: 342] [Article Influence: 69.6] [Reference Citation Analysis]
229 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 74] [Cited by in F6Publishing: 49] [Article Influence: 14.8] [Reference Citation Analysis]
230 Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther 2019;50:809-21. [PMID: 31475372 DOI: 10.1111/apt.15464] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
231 Li Z, Zhou Z, Hu L, Deng L, Ren Q, Zhang L. ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis. Pharmacol Res 2020;159:105035. [PMID: 32562818 DOI: 10.1016/j.phrs.2020.105035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
232 Lee S, Kim S, Hwang S, Cherrington NJ, Ryu DY. Dysregulated expression of proteins associated with ER stress, autophagy and apoptosis in tissues from nonalcoholic fatty liver disease. Oncotarget 2017;8:63370-81. [PMID: 28968997 DOI: 10.18632/oncotarget.18812] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
233 Kim D, Yoo ER, Li AA, Tighe SP, Cholankeril G, Ahmed A. Trends in Hospitalizations for Clostridioides difficile Infection in End-Stage Liver Disease, 2005–2014. Dig Dis Sci 2021;66:296-307. [DOI: 10.1007/s10620-020-06162-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Samji NS, Verma R, Satapathy SK. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. J Clin Exp Hepatol 2019;9:497-505. [PMID: 31516266 DOI: 10.1016/j.jceh.2019.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
235 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
236 Hemming AW. Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:519-38. [DOI: 10.1016/j.soc.2019.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
237 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
238 Younossi ZM. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis. Clin Gastroenterol Hepatol 2017;15:1144-7. [PMID: 28549675 DOI: 10.1016/j.cgh.2017.05.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
239 Ladhani S, Ohri A, Wong RJ. Disparities in Hepatocellular Carcinoma Surveillance: Dissecting the Roles of Patient, Provider, and Health System Factors. Journal of Clinical Gastroenterology 2020;54:218-26. [DOI: 10.1097/mcg.0000000000001313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
240 Younossi ZM. Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. Hepatology 2018;68:2405-12. [PMID: 30070714 DOI: 10.1002/hep.30125] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
241 Mungamuri SK, Mavuduru VA. Role of epigenetic alterations in aflatoxin‐induced hepatocellular carcinoma. Liver Cancer International 2020;1:41-50. [DOI: 10.1002/lci2.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
242 Drolz A, Wolter S, Wehmeyer MH, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse AW, Mann O, Kluwe J. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond) 2021. [PMID: 34168277 DOI: 10.1038/s41366-021-00881-8] [Reference Citation Analysis]
243 Esmaili S, Langfelder P, Belgard TG, Vitale D, Azardaryany MK, Alipour Talesh G, Ramezani-Moghadam M, Ho V, Dvorkin D, Dervish S, Gloss BS, Grønbæk H, Liddle C, George J. Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. Cell Syst 2021;12:432-445.e7. [PMID: 33957084 DOI: 10.1016/j.cels.2021.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
244 C. Gordon S, Fraysse J, Li S, Ozbay AB, Wong RJ. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. Am J Gastroenterol 2020;115:562-74. [DOI: 10.14309/ajg.0000000000000484] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
245 Deng Y, Pang Q, Miao RC, Chen W, Zhou YY, Bi JB, Liu SS, Zhang JY, Qu K, Liu C. Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma. Onco Targets Ther 2016;9:5317-28. [PMID: 27601923 DOI: 10.2147/OTT.S109736] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
246 Senni N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, Sartor C, Lagoutte I, Gougelet A, Terris B, Gilgenkrantz H, Perret C, Colnot S, Bossard P. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut 2019;68:322-34. [PMID: 29650531 DOI: 10.1136/gutjnl-2017-315448] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 18.3] [Reference Citation Analysis]
247 Vieira Barbosa J, Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Hepatol Commun 2021;5:158-67. [PMID: 33553966 DOI: 10.1002/hep4.1618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
248 Yang JD, Ahmed Mohammed H, Harmsen WS, Enders F, Gores GJ, Roberts LR. Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study. J Clin Gastroenterol 2017;51:742-8. [PMID: 28445235 DOI: 10.1097/MCG.0000000000000810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
249 Tiniakos DG, Maurício J, Reeves HL. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View. Adv Exp Med Biol 2018;1032:55-69. [PMID: 30362090 DOI: 10.1007/978-3-319-98788-0_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
250 Song Y, Wu W, Sheng L, Jiang B, Li X, Cai K. Chrysin ameliorates hepatic steatosis induced by a diet deficient in methionine and choline by inducing the secretion of hepatocyte nuclear factor 4α-dependent very low-density lipoprotein. J Biochem Mol Toxicol 2020;34:e22497. [PMID: 32220030 DOI: 10.1002/jbt.22497] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
251 Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:3682. [PMID: 30842500 DOI: 10.1038/s41598-019-39998-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
252 Degasperi E, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2016;1:156-164. [PMID: 28404072 DOI: 10.1016/s2468-1253(16)30018-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
253 Liang XY, Hong FF, Yang SL. Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:1871-83. [PMID: 33953586 DOI: 10.2147/DMSO.S304817] [Reference Citation Analysis]
254 Bajaj J, Brenner D, Cai Q, Cash B, Crowell M, Dibaise J, Gallegos-orozco J, Gardner T, Gyawali C, Ha C, Holtmann G, Jamil L, Kaplan G, Karsan H, Kinoshita Y, Lebwohl B, Leontiadis G, Lichtenstein G, Longstreth G, Muthusamy V, Oxentenko A, Pimentel M, Pisegna J, Rubenstein J, Russo M, Saini S, Samadder N, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy B. Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. Am J Gastroenterol 2020;115:1007-18. [DOI: 10.14309/ajg.0000000000000709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology. 2017;152:1656-1670. [PMID: 28192107 DOI: 10.1053/j.gastro.2016.12.052] [Cited by in Crossref: 81] [Cited by in F6Publishing: 52] [Article Influence: 16.2] [Reference Citation Analysis]
256 Wang Z, Gu X, Thrift AP. Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study. PLoS One 2019;14:e0214721. [PMID: 30943273 DOI: 10.1371/journal.pone.0214721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
257 Zhu X, Bian H, Gao X. The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. Molecules 2016;21:E1336. [PMID: 27754444 DOI: 10.3390/molecules21101336] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
258 Velázquez KT, Enos RT, Bader JE, Sougiannis AT, Carson MS, Chatzistamou I, Carson JA, Nagarkatti PS, Nagarkatti M, Murphy EA. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. World J Hepatol 2019; 11(8): 619-637 [PMID: 31528245 DOI: 10.4254/wjh.v11.i8.619] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
259 Tommasi S, Besaratinia A. DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E2791. [PMID: 31387232 DOI: 10.3390/ijerph16152791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
260 Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. The Lancet Diabetes & Endocrinology 2022;10:284-96. [DOI: 10.1016/s2213-8587(22)00003-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
261 Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71:793-801. [PMID: 31279902 DOI: 10.1016/j.jhep.2019.06.021] [Cited by in Crossref: 295] [Cited by in F6Publishing: 289] [Article Influence: 98.3] [Reference Citation Analysis]
262 Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904. [PMID: 29886156 DOI: 10.1016/j.jhep.2018.05.036] [Cited by in Crossref: 381] [Cited by in F6Publishing: 362] [Article Influence: 95.3] [Reference Citation Analysis]
263 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
264 Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol 2020;27:S138-43. [PMID: 33343207 DOI: 10.3747/co.27.7181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
265 Moussa I, Day RS, Li R, Kaseb A, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Med 2021;10:7308-19. [PMID: 34535983 DOI: 10.1002/cam4.4256] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
266 Liu D, Wong CC, Fu L, Chen H, Zhao L, Li C, Zhou Y, Zhang Y, Xu W, Yang Y, Wu B, Cheng G, Lai PB, Wong N, Sung JJY, Yu J. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med 2018;10:eaap9840. [PMID: 29669855 DOI: 10.1126/scitranslmed.aap9840] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 22.0] [Reference Citation Analysis]
267 Benhammou JN, Aby ES, Shirvanian G, Manansala K, Hussain SK, Tong MJ. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma. Sci Rep 2020;10:9902. [PMID: 32555268 DOI: 10.1038/s41598-020-66507-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
268 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019;70:531-44. [DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 452] [Cited by in F6Publishing: 433] [Article Influence: 150.7] [Reference Citation Analysis]
269 Fukui N, Golabi P, Otgonsuren M, de Avila L, Bush H, Younossi Z. Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality. Aliment Pharmacol Ther 2018;47:680-8. [DOI: 10.1111/apt.14484] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
270 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 31.7] [Reference Citation Analysis]
271 Chen H, Wang J, Li Z, Lam CWK, Xiao Y, Wu Q, Zhang W. Consumption of Sugar-Sweetened Beverages Has a Dose-Dependent Effect on the Risk of Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Dose-Response Meta-Analysis. Int J Environ Res Public Health 2019;16:E2192. [PMID: 31234281 DOI: 10.3390/ijerph16122192] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
272 Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017;46:856-63. [PMID: 28857208 DOI: 10.1111/apt.14261] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
273 Zhang J, Ma X, Fan D. Ginsenoside CK ameliorates hepatic lipid accumulation via activating the LKB1/AMPK pathway in vitro and in vivo. Food Funct 2022. [PMID: 35018944 DOI: 10.1039/d1fo03026d] [Reference Citation Analysis]
274 Liu Y, Li H, Dong J, Ma L, Liao A, Rong Z, Zhou Z, Cao L, Wang F, Wang J, Wang A. mTOR and ERK regulate VKORC1 expression in both hepatoma cells and hepatocytes which influence blood coagulation. Clin Exp Med 2019;19:121-32. [PMID: 30306378 DOI: 10.1007/s10238-018-0528-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
275 Ho CM, Ho SL, Jeng YM, Lai YS, Chen YH, Lu SC, Chen HL, Chang PY, Hu RH, Lee PH. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease. J Inflamm (Lond) 2019;16:7. [PMID: 30983887 DOI: 10.1186/s12950-019-0211-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
276 Ge Y, Gu P, Wang W, Cao L, Zhang L, Li J, Mu W, Wang H. Benzo[a]pyrene stimulates miR-650 expression to promote the pathogenesis of fatty liver disease and hepatocellular carcinoma via SOCS3/JAK/STAT3 cascades. J Mol Cell Biol 2021:mjab052. [PMID: 34450627 DOI: 10.1093/jmcb/mjab052] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
277 Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract 2020;35:72-84. [PMID: 31840865 DOI: 10.1002/ncp.10449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
278 Hao YY, Cui WW, Gao HL, Wang MY, Liu Y, Li CR, Hou YL, Jia ZH. Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis. Pharm Biol 2022;60:274-81. [PMID: 35138995 DOI: 10.1080/13880209.2022.2029501] [Reference Citation Analysis]
279 Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
280 Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26:54-59. [PMID: 31726817 DOI: 10.3350/cmh.2019.0039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
281 Younossi ZM, Henry L, Bush H, Mishra A. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018;22:1-10. [PMID: 29128049 DOI: 10.1016/j.cld.2017.08.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
282 Guo HB, Wang JH. Impact of contrast ultrasound diagnosis for patients with liver cancer. Medicine (Baltimore) 2019;98:e15445. [PMID: 31083175 DOI: 10.1097/MD.0000000000015445] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
283 Bernal-reyes R, Castro-narro G, Malé-velázquez R, Carmona-sánchez R, González-huezo M, García-juárez I, Chávez-tapia N, Aguilar-salinas C, Aiza-haddad I, Ballesteros-amozurrutia M, Bosques-padilla F, Castillo-barradas M, Chávez-barrera J, Cisneros-garza L, Flores-calderón J, García-compeán D, Gutiérrez-grobe Y, Higuera de la Tijera M, Kershenobich-stalnikowitz D, Ladrón de Guevara-cetina L, Lizardi-cervera J, López-cossio J, Martínez-vázquez S, Márquez-guillén E, Méndez-sánchez N, Moreno-alcantar R, Poo-ramírez J, Ramos-martínez P, Rodríguez-hernández H, Sánchez-ávila J, Stoopen-rometti M, Torre-delgadillo A, Torres-villalobos G, Trejo-estrada R, Uribe-esquivel M, Velarde-ruiz Velasco J. The Mexican consensus on nonalcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2019;84:69-99. [DOI: 10.1016/j.rgmxen.2019.02.003] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
284 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
285 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
286 Mazhar K. The Future of Nonalcoholic Fatty Liver Disease Treatment. Med Clin North Am 2019;103:57-69. [PMID: 30466676 DOI: 10.1016/j.mcna.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
287 Burton A, Balachandrakumar VK, Driver RJ, Tataru D, Paley L, Marshall A, Alexander G, Rowe IA, Palmer DH, Cross TJS; HCC-UK/BASL/NCRAS Partnership. Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England. Br J Cancer 2021. [PMID: 34837073 DOI: 10.1038/s41416-021-01509-4] [Reference Citation Analysis]
288 Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 2019;69:2672-82. [PMID: 30179269 DOI: 10.1002/hep.30251] [Cited by in Crossref: 593] [Cited by in F6Publishing: 484] [Article Influence: 197.7] [Reference Citation Analysis]
289 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
290 Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017; 8(6): 429-436 [PMID: 29291167 DOI: 10.5306/wjco.v8.i6.429] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
291 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
292 Xia Y, Wu Q, Dai H, Lv J, Liu Y, Sun H, Jiang Y, Chang Q, Niu K, Zhao Y. Associations of Nutritional, Lifestyle, and Metabolic Factors With Non-alcoholic Fatty Liver Disease: An Umbrella Review With More Than 380,000 Participants. Front Nutr 2021;8:642509. [PMID: 34604270 DOI: 10.3389/fnut.2021.642509] [Reference Citation Analysis]
293 Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol 2020;8:76-86. [PMID: 32274348 DOI: 10.14218/JCTH.2019.00051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
294 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016;33:291-319. [PMID: 26921205 DOI: 10.1007/s12325-016-0306-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
295 Labenz C, Prenosil V, Koch S, Huber Y, Marquardt JU, Schattenberg JM, Galle PR, Weinmann A, Wörns MA. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Dig Dis 2018;36:78-88. [PMID: 28675895 DOI: 10.1159/000477578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
296 Lleo A, de Boer YS, Liberal R, Colombo M. The risk of liver cancer in autoimmune liver diseases. Ther Adv Med Oncol 2019;11:1758835919861914. [PMID: 31320937 DOI: 10.1177/1758835919861914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
297 Yang T, Hu LY, Li ZL, Liu K, Wu H, Xing H, Lau WY, Pawlik TM, Zeng YY, Zhou YH, Gu WM, Wang H, Chen TH, Han J, Li C, Wang MD, Wu MC, Shen F. Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC. J Gastrointest Surg 2020;24:320-9. [PMID: 30617773 DOI: 10.1007/s11605-018-04071-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
298 Reeves HL, Zaki MYW, Day CP. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Dig Dis Sci 2016;61:1234-45. [DOI: 10.1007/s10620-016-4085-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 11.8] [Reference Citation Analysis]
299 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
300 de Conti A, Ortega JF, Tryndyak V, Dreval K, Moreno FS, Rusyn I, Beland FA, Pogribny IP. MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis. Oncotarget. 2017;8:88517-88528. [PMID: 29179453 DOI: 10.18632/oncotarget.19774] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
301 Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The Lancet Diabetes & Endocrinology 2019;7:313-24. [DOI: 10.1016/s2213-8587(18)30154-2] [Cited by in Crossref: 220] [Cited by in F6Publishing: 115] [Article Influence: 73.3] [Reference Citation Analysis]
302 Wang Z, Zhao X, Chen S, Wang Y, Cao L, Liao W, Sun Y, Wang X, Zheng Y, Wu S, Wang L. Associations Between Nonalcoholic Fatty Liver Disease and Cancers in a Large Cohort in China. Clin Gastroenterol Hepatol 2021;19:788-796.e4. [PMID: 32407969 DOI: 10.1016/j.cgh.2020.05.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
303 Léveillé M, Estall JL. Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites 2019;9:E233. [PMID: 31623280 DOI: 10.3390/metabo9100233] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
304 Weinfurtner K, Dodge JL, Yao FYK, Mehta N. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. Transplant Direct 2020;6:e605. [PMID: 33134485 DOI: 10.1097/TXD.0000000000001060] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
305 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Reference Citation Analysis]
306 Leung JC, Loong TC, Wei JL, Wong GL, Chan AW, Choi PC, Shu SS, Chim AM, Chan HL, Wong VW. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology 2017;65:54-64. [PMID: 27339817 DOI: 10.1002/hep.28697] [Cited by in Crossref: 163] [Cited by in F6Publishing: 150] [Article Influence: 32.6] [Reference Citation Analysis]
307 Qiu Q, Wang W, Zhao X, Chen Y, Zhao S, Zhu J, Xu X, Geng R. Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver. Bioorg Chem 2020;104:104262. [PMID: 32919135 DOI: 10.1016/j.bioorg.2020.104262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
308 Gild P, Cole AP, Krasnova A, Dickerman BA, von Landenberg N, Sun M, Mucci LA, Lipsitz SR, Chun FK, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Trinh Q. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology 2018;200:573-81. [DOI: 10.1016/j.juro.2018.03.135] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
309 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
310 Ozawa Y, Tamura T, Owada Y, Shimizu Y, Kemmochi A, Hisakura K, Matsuzaka T, Shimano H, Isoda H, Ohkohchi N. Evaluation of safety for hepatectomy in a novel mouse model with nonalcoholic-steatohepatitis. World J Gastroenterol 2018; 24(15): 1622-1631 [PMID: 29686469 DOI: 10.3748/wjg.v24.i15.1622] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
311 Lai Z, Chen J, Ding C, Wong K, Chen X, Pu L, Huang Q, Chen X, Cheng Z, Liu Y, Tan X, Zhu H, Wang L. Association of Hepatic Global DNA Methylation and Serum One-Carbon Metabolites with Histological Severity in Patients with NAFLD. Obesity (Silver Spring) 2020;28:197-205. [PMID: 31785086 DOI: 10.1002/oby.22667] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
312 Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, Nguyen MH. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. Hepatol Commun 2021;5:122-32. [PMID: 33437906 DOI: 10.1002/hep4.1606] [Reference Citation Analysis]
313 Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol. 2021;74:775-782. [PMID: 33248170 DOI: 10.1016/j.jhep.2020.11.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
314 Sayiner M, Golabi P, Younossi ZM. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Dig Dis Sci 2019;64:910-7. [DOI: 10.1007/s10620-019-05537-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 28.7] [Reference Citation Analysis]
315 Ahmad MI, Khan MU, Kodali S, Shetty A, Bell SM, Victor D. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. JHC 2022;Volume 9:477-96. [DOI: 10.2147/jhc.s344559] [Reference Citation Analysis]
316 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
317 Atarashi M, Izawa T, Miyagi R, Ohji S, Hashimoto A, Kuwamura M, Yamate J. Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. Nutrients 2018;10:E175. [PMID: 29401710 DOI: 10.3390/nu10020175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
318 Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49:471-483. [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147] [Cited by in Crossref: 161] [Cited by in F6Publishing: 152] [Article Influence: 32.2] [Reference Citation Analysis]
319 Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17. [PMID: 31347138 DOI: 10.1007/s15010-019-01345-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 11.7] [Reference Citation Analysis]
320 Baffy G. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 63-77. [DOI: 10.1007/978-981-10-8684-7_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
321 Raza S, Rajak S, Anjum B, Sinha RA. Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. Hepatoma Res 2019;5:42. [PMID: 31867441 DOI: 10.20517/2394-5079.2019.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
322 Patel YA, Berg CL, Moylan CA. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Dig Dis Sci. 2016;61:1406-1416. [PMID: 26815171 DOI: 10.1007/s10620-016-4035-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
323 Webel AR, Schexnayder J, Cioe PA, Zuñiga JA. A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science. J Assoc Nurses AIDS Care 2021;32:322-46. [PMID: 33595986 DOI: 10.1097/JNC.0000000000000240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
324 Younossi Z, Henry L. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. Gastroenterology. 2016;150:1778-1785. [PMID: 26980624 DOI: 10.1053/j.gastro.2016.03.005] [Cited by in Crossref: 141] [Cited by in F6Publishing: 123] [Article Influence: 23.5] [Reference Citation Analysis]
325 Musto J, Spengler EK, German MN. Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2021;20:97-107. [DOI: 10.1007/s11901-021-00568-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245. [PMID: 28975830 DOI: 10.1177/1073274817729245] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 38.8] [Reference Citation Analysis]
327 Balakrishnan M, Patel P, Dunn-valadez S, Dao C, Khan V, Ali H, El-serag L, Hernaez R, Sisson A, Thrift AP, Liu Y, El-serag HB, Kanwal F. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2021;19:61-71.e15. [DOI: 10.1016/j.cgh.2020.04.067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
328 Heredia NI, Zhang X, Balakrishnan M, Daniel CR, Hwang JP, McNeill LH, Thrift AP. Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017-2018. Prev Med 2022;154:106903. [PMID: 34861339 DOI: 10.1016/j.ypmed.2021.106903] [Reference Citation Analysis]
329 Wong VW, Chalasani N. Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes. J Hepatol 2016;64:1211-3. [PMID: 26921688 DOI: 10.1016/j.jhep.2016.02.032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
330 He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, Huang ZM. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11:e0162368. [PMID: 27711128 DOI: 10.1371/journal.pone.0162368] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
331 Kogiso T, Tokushige K. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:516. [PMID: 33572797 DOI: 10.3390/cancers13030516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
332 Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J, Feurstein B, Popp W, Karam V, Muiesan P, O'Grady J, Jamieson N, Wigmore SJ, Pirenne J, Malek-Hosseini SA, Hidalgo E, Tokat Y, Paul A, Pratschke J, Bartels M, Trunecka P, Settmacher U, Pinzani M, Duvoux C, Newsome PN, Schneeberger S; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019;71:313-322. [PMID: 31071367 DOI: 10.1016/j.jhep.2019.04.011] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 23.7] [Reference Citation Analysis]
333 Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Aliment Pharmacol Ther 2022;55:820-7. [PMID: 35229334 DOI: 10.1111/apt.16844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
334 Johnston MP, Patel J, Byrne CD. Update on cardiovascular risk in nonalcoholic fatty liver disease. Curr Opin Cardiol 2021;36:478-86. [PMID: 34059612 DOI: 10.1097/HCO.0000000000000861] [Reference Citation Analysis]
335 Rattanasupar A, Chang A, Prateepchaiboon T, Pungpipattrakul N, Akarapatima K, Songjamrat A, Pakdeejit S, Prachayakul V, Piratvisuth T. Impact of alcohol consumption on treatment outcome of hepatocellular carcinoma patients with viral hepatitis who underwent transarterial chemoembolization . World J Hepatol 2022; 14(6): 1162-1172 [DOI: 10.4254/wjh.v14.i6.1162] [Reference Citation Analysis]
336 Kim K, Choi S, Lee G, Son JS, Kim KH, Park SM. Association of weight change in young adulthood with subsequent risk of hepatocellular carcinoma: a national cohort study. Eur J Cancer Prev 2021;30:211-9. [PMID: 32925510 DOI: 10.1097/CEJ.0000000000000610] [Reference Citation Analysis]
337 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
338 Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology 2019;70:1119-33. [PMID: 31070259 DOI: 10.1002/hep.30702] [Cited by in Crossref: 162] [Cited by in F6Publishing: 133] [Article Influence: 54.0] [Reference Citation Analysis]
339 Pogribny IP, Dreval K, Kindrat I, Melnyk S, Jimenez L, de Conti A, Tryndyak V, Pogribna M, Ortega JF, James SJ. Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma. FASEB J. 2018;32:1591-1601. [PMID: 29127188 DOI: 10.1096/fj.201700866r] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
340 Zeng J, Yang RX, Sun C, Pan Q, Zhang RN, Chen GY, Hu Y, Fan JG. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol 2020; 26(15): 1792-1804 [PMID: 32351294 DOI: 10.3748/wjg.v26.i15.1792] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
341 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
342 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. In: Hamdy Gad E, editor. Nonalcoholic Fatty Liver Disease - An Update. IntechOpen; 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Xu G, Wang YM, Ying MM, Chen SD, Li ZR, Ma HL, Zheng MH, Wu J, Ding C. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis. Clin Mol Hepatol 2021;27:329-45. [PMID: 33465844 DOI: 10.3350/cmh.2020.0261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
344 Shi T, Kobara H, Oura K, Masaki T. Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes. J Hepatocell Carcinoma 2021;8:45-55. [PMID: 33604315 DOI: 10.2147/JHC.S274933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Reference Citation Analysis]
346 Wong CR, Nguyen MH, Lim JK. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22(37): 8294-8303 [PMID: 27729736 DOI: 10.3748/wjg.v22.i37.8294] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
347 Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. Hepatology 2019;69:564-72. [PMID: 30180285 DOI: 10.1002/hep.30254] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 26.7] [Reference Citation Analysis]
348 Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis. 2018;22:11-21. [PMID: 29128051 DOI: 10.1016/j.cld.2017.08.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 19.8] [Reference Citation Analysis]
349 Aller R, Fernández-rodríguez C, lo Iacono O, Bañares R, Abad J, Carrión JA, García-monzón C, Caballería J, Berenguer M, Rodríguez-perálvarez M, Miranda JL, Vilar-gómez E, Crespo J, García-cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterología y Hepatología (English Edition) 2018;41:328-49. [DOI: 10.1016/j.gastre.2018.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
350 Luo X, Li Y, Shang Q, Liu H, Song L. Role of Diffusional Kurtosis Imaging in Evaluating the Efficacy of Transcatheter Arterial Chemoembolization in Patients with Liver Cancer. Cancer Biother Radiopharm 2019;34:614-20. [PMID: 31560562 DOI: 10.1089/cbr.2019.2878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
351 Qin J, Higashi T, Nakagawa S, Fujiwara N, Yamashita YI, Beppu T, Baba H, Kobayashi M, Kumada H, Gunasekaran G, Schiano TD, Thung SN, Fiel MI, Hoshida Y, Ward SC. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights. Am J Surg Pathol 2020;44:1406-12. [PMID: 32618599 DOI: 10.1097/PAS.0000000000001533] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
352 Li C, Liu Q, Xie L. Suppressing NLRP2 expression accelerates hepatic steatosis: A mechanism involving inflammation and oxidative stress. Biochem Biophys Res Commun 2018;507:22-9. [PMID: 30454891 DOI: 10.1016/j.bbrc.2018.10.132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
353 Wong VW. Current Prevention and Treatment Options for NAFLD. Adv Exp Med Biol 2018;1061:149-57. [PMID: 29956213 DOI: 10.1007/978-981-10-8684-7_12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
354 Lafnoune A, Lee S, Heo J, Daoudi K, Darkaoui B, Chakir S, Cadi R, Mounaji K, Shum D, Seo H, Oukkache N. Anti-Cancer Activity of Buthus occitanus Venom on Hepatocellular Carcinoma in 3D Cell Culture. Molecules 2022;27:2219. [DOI: 10.3390/molecules27072219] [Reference Citation Analysis]
355 Morio B, Panthu B, Bassot A, Rieusset J. Role of mitochondria in liver metabolic health and diseases. Cell Calcium 2021;94:102336. [PMID: 33387847 DOI: 10.1016/j.ceca.2020.102336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
356 Villavicencio EA, Crocker RM, Garcia DO. A Qualitative Analysis of Mexican-Origin Men's Knowledge and Cultural Attitudes Toward Non-Alcoholic Fatty Liver Disease and Interest in Risk Reduction. Am J Mens Health 2021;15:15579883211063335. [PMID: 34872379 DOI: 10.1177/15579883211063335] [Reference Citation Analysis]
357 Yen YH, Cheng YF, Wang JH, Lin CC, Wang CC. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLoS One 2021;16:e0244939. [PMID: 33439893 DOI: 10.1371/journal.pone.0244939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
358 Zhao L, Deng C, Lin Z, Giovannucci E, Zhang X. Dietary Fats, Serum Cholesterol and Liver Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Studies. Cancers (Basel) 2021;13:1580. [PMID: 33808094 DOI: 10.3390/cancers13071580] [Reference Citation Analysis]
359 deLemos A, Patel M, Gawrieh S, Burney H, Dakhoul L, Miller E, Scanga A, Kettler C, Liu H, Roche P, Wattacheril J, Chalasani N. Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study. Clin Transl Gastroenterol 2020;11:e00139. [PMID: 32352723 DOI: 10.14309/ctg.0000000000000139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
360 Lin TY, Yeh ML, Huang CF, Huang CI, Dai CY, Hsieh MH, Chen SC, Huang JF, Yu ML, Chuang WL. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. Eur J Gastroenterol Hepatol 2019;31:224-9. [PMID: 30308578 DOI: 10.1097/MEG.0000000000001285] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
361 Bzowej NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Curr Opin Organ Transplant. 2018;23:169-174. [PMID: 29356708 DOI: 10.1097/mot.0000000000000502] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
362 Wang L, Zhang A, Liu W, Liu H, Su F, Qi L. Effects of dexmedetomidine on perioperative stress response, inflammation and immune function in patients with different degrees of liver cirrhosis. Exp Ther Med 2018;16:3869-74. [PMID: 30344663 DOI: 10.3892/etm.2018.6665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
363 Moussa I, Day RS, Li R, Du XL, Kaseb AO, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients 2021;13:2011. [PMID: 34208122 DOI: 10.3390/nu13062011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J. Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol 2017; 9(7): 385-390 [PMID: 28321274 DOI: 10.4254/wjh.v9.i7.385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
365 Sheng N, Wang Y, Xie Y, Chen S, Lu J, Zhang Z, Li M, Shan Q, Wu D, Zheng G, Zheng Y, Fan S. High expression of LASS2 is associated with unfavorable prognosis in patients with ovarian cancer. J Cell Physiol 2019;234:13001-13. [PMID: 30537159 DOI: 10.1002/jcp.27970] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
366 Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol 2017; 23(36): 6571-6592 [PMID: 29085206 DOI: 10.3748/wjg.v23.i36.6571] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 71] [Article Influence: 16.0] [Reference Citation Analysis]
367 Hu L, Zhou Z, Deng L, Ren Q, Cai Z, Wang B, Li Z, Wang G. HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis. J Pharm Pharmacol 2020;72:1564-73. [PMID: 32734608 DOI: 10.1111/jphp.13342] [Reference Citation Analysis]
368 Kabarra K, Golabi P, Younossi ZM. Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect 2021;10:R240-7. [PMID: 34486981 DOI: 10.1530/EC-21-0048] [Reference Citation Analysis]
369 Yoon CH, Jin YJ, Lee JW. Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area. Eur J Gastroenterol Hepatol 2018;30:1090-6. [PMID: 29847489 DOI: 10.1097/MEG.0000000000001174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
370 Zhou X, Li Y, Zhang X, Guan YY, Puentes Y, Zhang F, Speliotes EK, Ji L. Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort. Diabetes Metab Res Rev 2019;35:e3156. [PMID: 30892820 DOI: 10.1002/dmrr.3156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
371 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018;68:361-71. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 204] [Cited by in F6Publishing: 171] [Article Influence: 51.0] [Reference Citation Analysis]
372 Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer 2021;162:76-98. [PMID: 34954439 DOI: 10.1016/j.ejca.2021.11.024] [Reference Citation Analysis]
373 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
374 Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med 2020;287:711-22. [DOI: 10.1111/joim.13035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
375 Mospan AR, Morris HL, Fried MW. Real-world evidence in hepatocellular carcinoma. Liver Int 2021;41 Suppl 1:61-7. [PMID: 34155788 DOI: 10.1111/liv.14864] [Reference Citation Analysis]
376 Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577-86. [PMID: 27543837 DOI: 10.1002/hep.28785] [Cited by in Crossref: 581] [Cited by in F6Publishing: 513] [Article Influence: 96.8] [Reference Citation Analysis]
377 Cheng Y, Zhang K, Chen Y, Li Y, Li Y, Fu K, Feng R. Associations between Dietary Nutrient Intakes and Hepatic Lipid Contents in NAFLD Patients Quantified by ¹H-MRS and Dual-Echo MRI. Nutrients 2016;8:E527. [PMID: 27618908 DOI: 10.3390/nu8090527] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
378 Kumar R, Goh BG, Kam JW, Chang PE, Tan CK. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. Clin Mol Hepatol 2020;26:196-208. [PMID: 31914720 DOI: 10.3350/cmh.2019.0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
379 Benhammou JN, Lin J, Aby ES, Markovic D, Raman SS, Lu DS, Tong MJ. Nonalcoholic fatty liver disease-related hepatocellular carcinoma growth rates and their clinical outcomes. Hepatoma Res 2021;7:70. [PMID: 34966854 DOI: 10.20517/2394-5079.2021.74] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
380 Wongjarupong N, Assavapongpaiboon B, Susantitaphong P, Cheungpasitporn W, Treeprasertsuk S, Rerknimitr R, Chaiteerakij R. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2017;17:149. [PMID: 29216833 DOI: 10.1186/s12876-017-0696-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
381 Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, Smircic Duvnjak L. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2021;9:51-9. [PMID: 33604255 DOI: 10.14218/JCTH.2020.00057] [Reference Citation Analysis]
382 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 2734] [Cited by in F6Publishing: 2282] [Article Influence: 683.5] [Reference Citation Analysis]
383 Tête A, Gallais I, Imran M, Legoff L, Martin-Chouly C, Sparfel L, Bescher M, Sergent O, Podechard N, Lagadic-Gossmann D. MEHP/ethanol co-exposure favors the death of steatotic hepatocytes, possibly through CYP4A and ADH involvement. Food Chem Toxicol 2020;146:111798. [PMID: 33022287 DOI: 10.1016/j.fct.2020.111798] [Reference Citation Analysis]
384 Li F, Ou Q, Lai Z, Pu L, Chen X, Wang L, Sun L, Liang X, Wang Y, Xu H, Wei J, Wu F, Zhu H, Wang L. The Co-occurrence of Chronic Hepatitis B and Fibrosis Is Associated With a Decrease in Hepatic Global DNA Methylation Levels in Patients With Non-alcoholic Fatty Liver Disease. Front Genet 2021;12:671552. [PMID: 34335686 DOI: 10.3389/fgene.2021.671552] [Reference Citation Analysis]
385 Wong VW, Petta S, Hiriart J, Cammà C, Wong GL, Marra F, Vergniol J, Chan AW, Tuttolomondo A, Merrouche W, Chan HL, Le Bail B, Arena U, Craxì A, de Lédinghen V. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. Journal of Hepatology 2017;67:577-84. [DOI: 10.1016/j.jhep.2017.05.005] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 13.6] [Reference Citation Analysis]
386 Zhou J, Liu J, Sheng H, You N, Chen J, Mi X, Yang W, Zang S, Shi J; Chinese NAFLD Clinical Research Network (CNAFLD CRN). Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study. Adv Ther 2019;36:880-95. [PMID: 30820874 DOI: 10.1007/s12325-019-00902-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
387 Sung F, Yeh Y, Muo C, Hsu C, Tsai W, Hsu Y. Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022;14:825. [DOI: 10.3390/cancers14030825] [Reference Citation Analysis]
388 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Reference Citation Analysis]
389 Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells 2021;10:2034. [PMID: 34440803 DOI: 10.3390/cells10082034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
390 Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine (Baltimore) 2020;99:e23506. [PMID: 33327291 DOI: 10.1097/MD.0000000000023506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Mano Y, Yoshio S, Shoji H, Tomonari S, Aoki Y, Aoyanagi N, Okamoto T, Matsuura Y, Osawa Y, Kimura K, Yugawa K, Wang H, Oda Y, Yoshizumi T, Maehara Y, Kanto T. Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. J Gastroenterol 2019;54:1007-18. [PMID: 30941514 DOI: 10.1007/s00535-019-01579-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
392 Alswat K, Aljumah AA, Sanai FM, Abaalkhail F, Alghamdi M, Al Hamoudi WK, Al Khathlan A, Al Quraishi H, Al Rifai A, Al Zaabi M, Babatin MA, Estes C, Hashim A, Razavi H. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol. 2018;24:211-219. [PMID: 29956688 DOI: 10.4103/sjg.sjg_122_18] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
393 Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021;119:154770. [PMID: 33864798 DOI: 10.1016/j.metabol.2021.154770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
394 Cammarota A, D'Alessio A, Pressiani T, Rimassa L, Personeni N. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs Aging 2021;38:579-91. [PMID: 34152589 DOI: 10.1007/s40266-021-00871-5] [Reference Citation Analysis]
395 Seki E. HEDGEHOG Signal in hepatocytes mediates macrophage recruitment: A new mechanism and potential therapeutic target for fatty liver disease. Hepatology 2016;63:1071-3. [PMID: 26638191 DOI: 10.1002/hep.28381] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
396 Conway RBN, Sudenga S, McClain D, Blot WJ. Diabetes and liver cancer risk: A stronger effect in Whites than Blacks? J Diabetes Complications 2021;35:107816. [PMID: 33323327 DOI: 10.1016/j.jdiacomp.2020.107816] [Reference Citation Analysis]
397 Zhang L, Tian R, Yao X, Zhang XJ, Zhang P, Huang Y, She ZG, Li H, Ji YX, Cai J. Milk Fat Globule-Epidermal Growth Factor-Factor 8 Improves Hepatic Steatosis and Inflammation. Hepatology 2021;73:586-605. [PMID: 32297339 DOI: 10.1002/hep.31277] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
398 Cunha GM, Guzman G, Correa De Mello LL, Trein B, Spina L, Bussade I, Marques Prata J, Sajoux I, Countinho W. Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity. Front Endocrinol (Lausanne) 2020;11:607. [PMID: 33042004 DOI: 10.3389/fendo.2020.00607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
399 Wang CR, Chen HW, Li Y, Zhou MY, Wong VK, Jiang ZH, Zhang W. Network Pharmacology Exploration Reveals Anti-Apoptosis as a Common Therapeutic Mechanism for Non-Alcoholic Fatty Liver Disease Treated with Blueberry Leaf Polyphenols. Nutrients 2021;13:4060. [PMID: 34836315 DOI: 10.3390/nu13114060] [Reference Citation Analysis]
400 Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? Journal of Hepatology 2018;68:519-25. [DOI: 10.1016/j.jhep.2017.11.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
401 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
402 Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 2021;75:1476-84. [PMID: 34453963 DOI: 10.1016/j.jhep.2021.08.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
403 Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol 2021;15:91-102. [PMID: 32933351 DOI: 10.1080/17474124.2021.1823213] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]